Literature DB >> 29933048

Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines.

Maria Ferraiuolo1, Claudio Pulito1, Megan Finch-Edmondson2, Etleva Korita1, Anna Maidecchi3, Sara Donzelli1, Paola Muti4, Massimo Serra5, Marius Sudol6, Sabrina Strano7, Giovanni Blandino8.   

Abstract

Osteosarcoma (OS) is the most aggressive type of primary solid tumor that develops in bone. Whilst conventional chemotherapy can improve survival rates, the outcome for patients with metastatic or recurrent OS remains poor, so novel treatment agents and strategies are required. Research into new anticancer therapies has paved the way for the utilisation of natural compounds as they are typically less expensive and less toxic compared to conventional chemotherapeutics. Previously published works indicate that Agave exhibits anticancer properties, however potential molecular mechanisms remain poorly understood. In the present study, we investigate the anticancer effects of Agave leaf extract in OS cells suggesting that Agave inhibits cell viability, colony formation, and cell migration, and can induce apoptosis in OS cell lines. Moreover, Agave sensitizes OS cells to cisplatin (CDDP) and radiation, to overcome chemo- and radio-resistance. We demonstrate that Agave extract induces a marked decrease of Yes Associated Protein (YAP) and Tafazzin (TAZ) mRNA and protein expression upon treatment. We propose an initial mechanism of action in which Agave induces YAP/TAZ protein degradation, followed by a secondary event whereby Agave inhibits YAP/TAZ transcription, effectively deregulating the Nuclear Factor kappa B (NF-κB) p65:p50 heterodimers responsible for transcriptional induction of YAP and TAZ.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Agave; Osteosarcoma; Proliferation; Saponins; YAP/TAZ

Mesh:

Substances:

Year:  2018        PMID: 29933048     DOI: 10.1016/j.canlet.2018.06.021

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

1.  cTAZ: a safeguard factor of antiviral response.

Authors:  Sabrina Strano; Giovanni Blandino
Journal:  EMBO Rep       Date:  2019-04-17       Impact factor: 8.807

2.  CLP36 promotes p53 deficient sarcoma progression through suppression of atrophin-1 interacting protein-4 (AIP-4)-dependent degradation of YAP1.

Authors:  Yixuan Lu; Yongxin Mu; Ju Chen; Xinyuan Guan; Ling Guo; Chuanyue Wu
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

3.  Targeting Transcription Factors in Cancer: From "Undruggable" to "Druggable".

Authors:  Zhipeng Tao; Xu Wu
Journal:  Methods Mol Biol       Date:  2023

4.  The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas.

Authors:  Ricardo Gargini; Berta Segura-Collar; Beatriz Herránz; Vega García-Escudero; Andrés Romero-Bravo; Felipe J Núñez; Daniel García-Pérez; Jacqueline Gutiérrez-Guamán; Angel Ayuso-Sacido; Joan Seoane; Angel Pérez-Núñez; Juan M Sepúlveda-Sánchez; Aurelio Hernández-Laín; María G Castro; Ramón García-Escudero; Jesús Ávila; Pilar Sánchez-Gómez
Journal:  Sci Transl Med       Date:  2020-01-22       Impact factor: 17.956

5.  YY1 is a cis-regulator in the organoid models of high mammographic density.

Authors:  Qingsu Cheng; Mina Khoshdeli; Bradley S Ferguson; Kosar Jabbari; Chongzhi Zang; Bahram Parvin
Journal:  Bioinformatics       Date:  2020-03-01       Impact factor: 6.937

6.  Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation.

Authors:  Valeria Canu; Sara Donzelli; Andrea Sacconi; Federica Lo Sardo; Claudio Pulito; Noa Bossel; Anna Di Benedetto; Paola Muti; Claudio Botti; Eytan Domany; Silvio Bicciato; Sabrina Strano; Yosef Yarden; Giovanni Blandino
Journal:  Cell Death Differ       Date:  2020-11-23       Impact factor: 15.828

Review 7.  Reciprocal Crosstalk Between YAP1/Hippo Pathway and the p53 Family Proteins: Mechanisms and Outcomes in Cancer.

Authors:  Nitin Raj; Rakesh Bam
Journal:  Front Cell Dev Biol       Date:  2019-08-09

8.  Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma.

Authors:  Claudio Pulito; Etleva Korita; Andrea Sacconi; Mariacristina Valerio; Luca Casadei; Federica Lo Sardo; Federica Mori; Maria Ferraiuolo; Giuseppe Grasso; Anna Maidecchi; Jacopo Lucci; Marius Sudol; Paola Muti; Giovanni Blandino; Sabrina Strano
Journal:  J Exp Clin Cancer Res       Date:  2019-08-09

Review 9.  The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis.

Authors:  Heinrich Kovar; Lisa Bierbaumer; Branka Radic-Sarikas
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

10.  ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.

Authors:  Cinzia Zucchini; Maria Cristina Manara; Camilla Cristalli; Marianna Carrabotta; Sara Greco; Rosa Simona Pinca; Cristina Ferrari; Lorena Landuzzi; Michela Pasello; Pier-Luigi Lollini; Marco Gambarotti; Davide Maria Donati; Katia Scotlandi
Journal:  J Exp Clin Cancer Res       Date:  2019-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.